WHO Plans to Develop Oversight Standards for Gene Editing Following Chinese Researcher’s Experiment

글 내용 전체보기

With 5 Gene Therapies Licensed From Penn, Passage Bio Launches With $115.5 Million Series A

글 내용 전체보기

New Government Funding Bill Provides FDA With Additional $269 Million

글 내용 전체보기

BioSpace Movers and Shakers: Feb. 15

글 내용 전체보기

Lundbeck and Otsuka’s Antipsychotic Drug Rexulti Fails Two Bipolar Phase III Trials

글 내용 전체보기

Bayer, Janssen and BMS Unveil Promising Data for Prostate Cancer at ASCO GU

글 내용 전체보기

Insys Trial Continues With Notorious Rap Video Played for Jurors

글 내용 전체보기

With New HQ, Boston’s Medidata Expects to Hire 600-800 Over Next 5 Years

글 내용 전체보기

Swayed by discounts, NICE finally backs Roche’s Perjeta for postsurgery breast cancer

글 내용 전체보기

Dr. Reddy’s racks up more repeat violations at Bachupally formulations plant

글 내용 전체보기

FiercePharmaAsia—AstraZeneca’s China business; Pfizer Japan valsartan recall; Xofluza resistance

글 내용 전체보기

Egalet’s 70% price increase shows the buy-and-hike strategy is alive and well

글 내용 전체보기

https://www.fiercebiotech.com/biotech/india-s-glenmark-spins-out-nmes-into-u-s-company

글 내용 전체보기

India’s Glenmark spins out NMEs into U.S. company

글 내용 전체보기

Chutes & Ladders—Sanofi’s CMO takes on chief digital officer role

글 내용 전체보기

FDA funding set to jump as Congress votes to avert shutdown

글 내용 전체보기

Novel immunotherapy prevents cervical, lung cancer in mice

글 내용 전체보기

AstraZeneca ups yields but takes $400m hit on plant closures

글 내용 전체보기

Drones to bioreactors: CDMO Culture Biosciences ready to fly high

글 내용 전체보기

Fierce competition between the human immune system and bacterial pathogens

글 내용 전체보기

Study fails to link phthalates and increased breast cancer risk

글 내용 전체보기